Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
The University of Tokyo · National Institute of Infectious Diseases · +1 more institution
Abstract
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB To the Editor: Three sublineages of the B.1.1.529(omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have serially transitioned into globally dominant formsfirst BA.1, then BA.2, and then BA.5.As of October 2022, most circulating omicron variants belong to BA.5.However, the prevalence of BQ.1.1 (a BA.5 subvariant) and XBB (a BA.2 subvariant) is increasing rapidly in several countries, including the United States and India.BA.2 and BA.5 variants have been shown to have less sensitivity to certain monoclonal antibodies than previously circulating variants of concern. 1-5Notably, as compared with BA.5 and BA.2,…
Citation impact
- FWCI
- 28.06
- Percentile
- 100%
- References
- 6
Authors
13Topics & keywords
- Monoclonal antibody
- Coronavirus disease 2019 (COVID-19)
- Antibody
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Virology
- Receptor
- Medicine
- Internal medicine
- Zero hunger